Your session is about to expire
← Back to Search
OCU400 for Retinitis Pigmentosa (OCU400 Trial)
OCU400 Trial Summary
This trial is testing a new treatment for retinitis pigmentosa, a degenerative eye disease. The treatment involves injecting a drug into the retina, and the trial will assess the safety of the treatment.
OCU400 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OCU400 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a neurological condition that affects your vision, making it difficult to measure your visual function.You have received gene therapy or cell therapy treatment before.You have a medical condition that is likely to significantly shorten your lifespan.You have received a gene therapy or cell therapy treatment in the past.You are unable to receive an injection under the retina.You have participated in a study testing a new drug or medical device within the last year.You cannot receive a subretinal injection for medical reasons.
- Group 1: Natural History Study (OCU400-104)
- Group 2: Adult Arm
- Group 3: Cohort 1 (Low Dose)
- Group 4: Cohort 2 (Mid Dose)
- Group 5: Cohort 3 (High Dose)
- Group 6: Pediatric Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 2 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are being treated as part of this experiment?
"In order for this clinical trial to move forward, 18 individuals who meet the pre-specified inclusion criteria must enroll. These patients can be based out of Ocugen Site 6 - Emory University in Atlanta, Georgia or Ocugen Site 8 - Mid Atlantic Retina - Wills Eye Hospital in Philadelphia, Pennsylvania."
Is this trial taking place in numerous stateside facilities?
"There are 8 clinical trial sites presently operational. They are situated in Atlanta, Chicago, Philadelphia and other cities. If you want to enroll in this study, it may be helpful to choose a location that is nearest to you so as to reduce travelling demands."
Can patients currently sign up for this clinical trial?
"The clinicaltrials.gov website contains information suggesting that this trial is still open to patients. This study was first posted on January 24th, 2022 and updated October 19th, 2022. There are 8 locations where a total of 18 people will be accepted into the trial."
What goals does this clinical trial hope to accomplish?
"The objective of this one year long clinical trial is to document Serious adverse events (SAEs). Other metrics that will be used to assess the efficacy of the intervention include changes in anti-hNR2E3 antibodies (gene), Intraocular pressure (IOP), and Indirect ophthalmoscopy."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- Ocugen Site 6 - Emory University: < 24 hours
- Ocugen Site 3 - Bascom Palmer Eye Institute: < 24 hours
- Ocugen Site 1 - Retina Foundation of the Southwest: < 24 hours
Share this study with friends
Copy Link
Messenger